Related Experiment Videos
Successful sentinel node identification in colon carcinoma using Patent Blue V
A E Braat1, J W A Oosterhuis, F C P Moll
1Department of Surgery, Isala klinieken, locatie Sophia, Dokter van Heesweg 2, P.O. Box 10400, 8000 GK Zwolle, The Netherlands. aebraat@home.nl
Summary
Patent Blue V effectively identifies sentinel lymph nodes in colon cancer patients. This method aids in detecting metastases, improving diagnostic accuracy for this malignancy.
Area of Science:
- Oncology
- Surgical Pathology
- Medical Imaging
Background:
- Sentinel lymph node biopsy is crucial for accurate cancer staging.
- Accurate identification of the sentinel node is essential for effective metastasis detection in colon carcinoma.
Purpose of the Study:
- To evaluate Patent Blue V as a tracer for sentinel node identification in colon carcinoma patients.
- To assess the efficacy and accuracy of Patent Blue V in lymphatic mapping for colorectal cancer.
Main Methods:
- 35 patients with colon carcinoma underwent lymphatic mapping using Patent Blue V.
- Patent Blue V was injected peritumourally, and identified sentinel nodes were pathologically evaluated.
- Immunohistochemical staining was used to detect micrometastases in sentinel nodes.
Main Results:
- Sentinel nodes were identified in 33 out of 35 patients.
- Metastases were found in the sentinel node of 10 patients, with 5 having metastases exclusively in this node.
- The study reported a sentinel node identification accuracy of 97% and sensitivity of 91%.
Conclusions:
- Patent Blue V is a reliable agent for sentinel node identification in colon cancer.
- The efficacy of Patent Blue V in sentinel node biopsy is comparable to other tracers like Lymphazurin.